Shares of Intrexon Corp. (NYSE:XON) traded down 7.2% on Tuesday . The stock traded as low as $23.61 and last traded at $23.61, with a volume of 702,962 shares trading hands. The stock had previously closed at $25.45.

Several analysts have weighed in on the stock. Griffin Securities reiterated a “buy” rating and set a $65.00 target price on shares of Intrexon Corp. in a research note on Tuesday, June 7th. Zacks Investment Research upgraded shares of Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $32.00 target price for the company in a research note on Tuesday, May 3rd. Wunderlich reiterated a “buy” rating and set a $50.00 target price on shares of Intrexon Corp. in a research note on Thursday, July 7th. Stifel Nicolaus reiterated a “buy” rating and set a $57.00 target price on shares of Intrexon Corp. in a research note on Wednesday, June 29th. Finally, JMP Securities reiterated a “buy” rating on shares of Intrexon Corp. in a research note on Sunday. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Intrexon Corp. has a consensus rating of “Hold” and an average target price of $47.23.

The company’s market capitalization is $2.98 billion. The firm has a 50 day moving average of $25.71 and a 200-day moving average of $29.70.

Intrexon Corp. (NYSE:XON) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.35. The firm earned $43.40 million during the quarter, compared to the consensus estimate of $46.26 million. During the same period last year, the company earned $0.25 earnings per share. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. On average, analysts forecast that Intrexon Corp. will post ($1.32) EPS for the current fiscal year.

In other Intrexon Corp. news, CEO Randal J. Kirk acquired 41,830 shares of Intrexon Corp. stock in a transaction dated Friday, May 13th. The stock was bought at an average cost of $23.92 per share, with a total value of $1,000,573.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Several large investors have bought and sold shares of XON. Morgan Stanley boosted its stake in Intrexon Corp. by 12.6% in the fourth quarter. Morgan Stanley now owns 3,162,236 shares of the company’s stock valued at $95,342,000 after buying an additional 354,559 shares in the last quarter. Oracle Investment Management Inc. boosted its stake in Intrexon Corp. by 15.9% in the fourth quarter. Oracle Investment Management Inc. now owns 932,585 shares of the company’s stock valued at $28,117,000 after buying an additional 127,708 shares in the last quarter. Trexquant Investment LP acquired a new stake in Intrexon Corp. during the fourth quarter valued at $2,590,000. California State Teachers Retirement System boosted its stake in Intrexon Corp. by 7.2% in the fourth quarter. California State Teachers Retirement System now owns 90,526 shares of the company’s stock valued at $2,729,000 after buying an additional 6,078 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in Intrexon Corp. by 30.1% in the fourth quarter. New York State Common Retirement Fund now owns 212,875 shares of the company’s stock valued at $6,418,000 after buying an additional 49,290 shares in the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.